🇺🇸 FDA
Patent

US 9315813

Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes

granted A61PA61P1/16A61P3/06

Quick answer

US patent 9315813 (Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes) held by Alnylam Pharmaceuticals, Inc. expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P1/16, A61P3/06, A61P43/00